Ross La Motte-Mohs, PhD (he/him/his)

Associate Director
Heme-Translational Medicine, Bristol Myers Squibb

Ross La Motte-Mohs, Ph.D.
Associate Director, Heme-Translational Medicine, Bristol Myers Squibb
Late-stage Biomarker Lead for BMS' Alnuctamab, a BCMA x CD3 T cell egnager (TCE).

Poster(s):

• P-025: Synergistic antitumor activity of the BCMA 2+1 T-cell engager (TCE) alnuctamab (ALNUC; BMS-986349; CC-93269) and CELMoD agents in multiple myeloma (MM) preclinical models
  Wednesday, September 27, 2023

  1:30 PM – 2:30 PM EEST